BackTheriva Biologics Overview

Theriva Biologics Long Term Debt

Track Theriva Biologics's long-term debt ($1.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.37M
135.27% YoYΔ $790000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Theriva Biologics Long Term Debt History

Loading

Theriva Biologics vs. peers: Long Term Debt Comparison

Loading

Theriva Biologics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Theriva Biologics (SYN) FAQ

As of the most recent data (June 2026), SYN shows a long-term debt of $1.4M. That compares with $580K in the prior-year period — up 135.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SYN's long-term debt is now $1.4M (was $580K) — a 135.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Theriva Biologics is outperforming or lagging.

Tracking SYN's long-term debt over time shows whether Theriva Biologics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.4M That compares with $580K in the prior-year period — up 135.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Theriva Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.4M) with ownership activity and broader fundamentals.

Theriva Biologics's long-term debt is $1.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.